For Immediate Release
Chicago, IL – November 1, 2022 – Stocks in this week’s article are Tandem Diabetes Care (
TNDM Quick Quote TNDM - Free Report) , Krispy Kreme ( DNUT Quick Quote DNUT - Free Report) , Caesars Entertainment ( CZR Quick Quote CZR - Free Report) and Vestas Wind Systems ( VWDRY Quick Quote VWDRY - Free Report) . Alleviate Stress by Dumping These 4 Toxic Stocks
Successful investing calls for the appropriate identification of overpriced stocks and correctly priced stocks. However, in practice, overhyped toxic stocks and fairly priced stocks are intermixed in the marketplace in such a way that it becomes difficult to distinguish between them. Investors who can correctly spot overpriced stocks and shun them at the right time are the ones likely to make a profit.
Usually, toxic stocks are fraught with huge debt loads and susceptible to external shocks. Also, the unjustifiably high price of the toxic stocks is short-lived as the intrinsic value of these stocks is less than their current price. Quite naturally, if you own such toxic stocks for a long period of time, you are sure to incur a huge loss of wealth
. Tandem Diabetes Care, Krispy Kreme, Caesars Entertainment and Vestas Wind Systems are a few such toxic stocks.
The higher price of the toxic stocks can be attributed to either an irrational exuberance associated with them or some serious fundamental lacuna associated with them. If you own such stocks for long, you are likely to see a big loss in your wealth.
On the other hand, if you can accurately pinpoint the toxic stocks, you are likely to gain by resorting to an investing strategy called short selling. This strategy allows you to sell a stock first and then buy it when the price falls.
While short selling excels in bear markets, it typically loses money in bull markets.
So, just like picking up stocks with strong growth potential, pinpointing toxic stocks and abandoning them at the right time is the key to protect your portfolio from big losses or make profits by short selling them.
Here are four of the 21 toxic stocks that showed up on the screen: Tandem Diabetes: Headquartered in California, TNDM designs, develops and markets products for people with insulin-dependent diabetes.
Tandem Diabetes currently carries a Zacks Rank #5 (Strong Sell) and has a VGM Score of F. The Zacks Consensus Estimate for TNDM's 2022 bottom line implies a year-over-year plunge of 200%. The consensus mark has deteriorated from earnings of 35 cents a share to a loss of 26 cents over the past 90 days. The company has a trailing four-quarter negative earnings surprise of 298%.
Krispy Kreme: Based in North Carolina, Krispy Kreme operates as a branded retailer and wholesaler of doughnuts, coffee and other complementary beverages and treats and packaged sweets.
DNUT currently carries a Zacks Rank #4 (Sell) and has a VGM Score of D. The Zacks Consensus Estimate for Krispy Kreme's 2022 bottom line implies a year-over-year decline of 19%. The consensus mark of earnings per share has moved south by a penny over the past 30 days. The company has a trailing four-quarter negative earnings surprise of 2%.
Caesars Entertainment: Headquartered in Nevada, Caesars Entertainment is a diversified gaming and hospitality company. Its primary source of revenues is gaming operations that include mobile, online gaming and sports betting.
CZR currently carries a Zacks Rank #4. The Zacks Consensus Estimate for Caesars Entertainment's 2022 bottom line is pegged at a loss of $2.82 a share The consensus mark of loss per share has widened 2 cents over the past seven days. The company has a trailing four-quarter negative earnings surprise of 381%.
Vestas Wind: Based in Denmark, Vestas Wind is engaged in the development, manufacture, sale, and maintenance of wind technology that uses the energy of the wind to generate electricity.
VWDRY currently carries a Zacks Rank #4 and has a VGM Score of D. The Zacks Consensus Estimate for Vestas Wind's 2022 bottom line implies a year-over-year plunge of 371.4%. The consensus mark of loss per share has moved south by 4 cents to 19 cents over the past 30 days. The company has a trailing four-quarter negative earnings surprise of 33.3%.
Get the rest of the stocks on the list and start putting this and other ideas to the test. It can all be done with the Research Wizard stock picking and backtesting software.
The Research Wizard is a great place to begin. It's easy to use. Everything is in plain language. And it's very intuitive. Start your Research Wizard trial today. And the next time you read an economic report, open up the Research Wizard, plug your finds in, and see what gems come out.
Click here to sign up for a free trial to the Research Wizard today. For the rest of this Screen of the Week article please visit Zacks.com at: https://www.zacks.com/stock/news/2010917/get-rid-of-your-stress-by-dumping-these-4-toxic-stocks Disclosure: Officers, directors and/or employees of Zacks Investment Research may own or have sold short securities and/or hold long and/or short positions in options that are mentioned in this material. An affiliated investment advisory firm may own or have sold short securities and/or hold long and/or short positions in options that are mentioned in this material. About Screen of the Week
Zacks.com created the first and best screening system on the web earning the distinction as the "#1 site for screening stocks" by Money Magazine. But powerful screening tools is just the start. That is why Zacks created the Screen of the Week to highlight profitable stock picking strategies that investors can actively use.
Strong Stocks that Should Be in the News
Many are little publicized and fly under the Wall Street radar. They're virtually unknown to the general public. Yet today's 220 Zacks Rank #1 "Strong Buys" were generated by the stock-picking system that has more than doubled the market from 1988 through 2016. Its average gain has been a stellar +25% per year.
See these high-potential stocks free >>.
Follow us on Twitter:
Join us on Facebook:
Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates.
Contact: Jim Giaquinto
Zacks.com provides investment resources and informs you of these resources, which you may choose to use in making your own investment decisions. Zacks is providing information on this resource to you subject to the Zacks "Terms and Conditions of Service" disclaimer.
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit
https://www.zacks.com/performancefor information about the performance numbers displayed in this press release.